MannKind Corporation (MNKD): Price and Financial Metrics

MannKind Corporation (MNKD): $4.53

0.10 (-2.16%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add MNKD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#111 of 363

in industry

MNKD Price/Volume Stats

Current price $4.53 52-week high $5.75
Prev. close $4.63 52-week low $3.17
Day low $4.49 Volume 2,578,139
Day high $4.74 Avg. volume 3,205,179
50-day MA $4.00 Dividend yield N/A
200-day MA $4.08 Market Cap 1.22B

MNKD Stock Price Chart Interactive Chart >

MNKD POWR Grades

  • MNKD scores best on the Growth dimension, with a Growth rank ahead of 96.47% of US stocks.
  • MNKD's strongest trending metric is Value; it's been moving up over the last 26 weeks.
  • MNKD's current lowest rank is in the Stability metric (where it is better than 17.43% of US stocks).

MNKD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MNKD is -0.7 -- better than just 5.88% of US stocks.
  • Price to trailing twelve month operating cash flow for MNKD is currently 99.35, higher than 97.11% of US stocks with positive operating cash flow.
  • Revenue growth over the past 12 months for MANNKIND CORP comes in at 131.61%, a number that bests 96.35% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MANNKIND CORP are EVLV, DVAX, LNSR, EVBG, and EOSE.
  • Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to www.mannkindcorp.com.

MNKD Valuation Summary

  • MNKD's price/sales ratio is 5.6; this is 33.33% higher than that of the median Healthcare stock.
  • MNKD's price/sales ratio has moved NA NA over the prior 236 months.

Below are key valuation metrics over time for MNKD.

Stock Date P/S P/B P/E EV/EBIT
MNKD 2023-12-29 5.6 -3.9 -31.4 -206.7
MNKD 2023-12-28 5.6 -4.0 -31.9 -209.3
MNKD 2023-12-27 5.6 -3.9 -31.5 -207.5
MNKD 2023-12-26 5.5 -3.9 -31.3 -206.2
MNKD 2023-12-22 5.5 -3.9 -31.0 -204.9
MNKD 2023-12-21 5.2 -3.7 -29.5 -197.1

MNKD Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -102.86%.
  • Its 3 year cash and equivalents growth rate is now at 91.81%.
  • Its year over year price growth rate is now at -23.63%.
Over the past 33 months, MNKD's revenue has gone up $13,188,000.

The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 76.226 -90.65 -97.514
2022-06-30 65.612 -77.761 -87.508
2022-03-31 69.998 -67.226 -94.008
2021-12-31 75.442 -61.709 -80.926
2021-09-30 81.37 -49.127 -79.276
2021-06-30 74.511 -47.403 -86.105

MNKD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNKD has a Quality Grade of C, ranking ahead of 42.97% of graded US stocks.
  • MNKD's asset turnover comes in at 0.384 -- ranking 124th of 680 Pharmaceutical Products stocks.
  • VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.

The table below shows MNKD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.384 0.611 -0.321
2021-03-31 0.424 0.627 -0.330
2020-12-31 0.673 0.622 -0.564
2020-09-30 0.673 0.595 -0.391
2020-06-30 0.666 0.529 -0.297
2020-03-31 0.705 0.516 -0.324

MNKD Price Target

For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.33 (Strong Buy)

MannKind Corporation (MNKD) Company Bio


MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.


MNKD Latest News Stream


Event/Time News Detail
Loading, please wait...

MNKD Latest Social Stream


Loading social stream, please wait...

View Full MNKD Social Stream

Latest MNKD News From Around the Web

Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.

MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, Ca

Yahoo | December 28, 2023

Insider Sell: CEO Michael Castagna Offloads 200,482 Shares of MannKind Corp (MNKD)

In a significant move within the pharmaceutical industry, CEO Michael Castagna has parted with a substantial number of shares in MannKind Corp (NASDAQ:MNKD).

Yahoo | December 17, 2023

High-Yield Haven: 3 Dividend Stocks to Secure Now

These are three different dividend stocks that have a great dividend yield and offer a reliable source of income.

Noah Bolton on InvestorPlace | December 6, 2023

Investors in MannKind (NASDAQ:MNKD) have seen solid returns of 115% over the past five years

It hasn't been the best quarter for MannKind Corporation ( NASDAQ:MNKD ) shareholders, since the share price has fallen...

Yahoo | December 3, 2023

MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript November 7, 2023 MannKind Corporation beats earnings expectations. Reported EPS is $0.01, expectations were $-0.02. Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2023, and will be available […]

Yahoo | November 8, 2023

Read More 'MNKD' Stories Here

MNKD Price Returns

1-mo 19.84%
3-mo 24.45%
6-mo 9.69%
1-year 10.76%
3-year 24.45%
5-year 129.95%
YTD 24.45%
2023 -30.93%
2022 20.59%
2021 39.62%
2020 142.64%
2019 21.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!